Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215614 | 0.87 | LMNA (0.39) | LMNAPTPN1BLM | |
| SCHEMBL27960321 | 0.85 | SMN1; SMN2 (0.32) | LMNAEPHX2 | |
| SCHEMBL7943134 | 0.83 | SMN1; SMN2 (0.44) | LMNAEPHX2 | |
| SCHEMBL23097684 | 0.82 | EPHX2 (0.33) | LMNAEPHX2 | |
| SCHEMBL29892290 | 0.82 | SMN1; SMN2 (0.37) | LMNAEPHX2 | |
| SCHEMBL27203930 | 0.82 | ALOX5 (0.33) | EPHX2 | |
| SCHEMBL29892792 | 0.82 | EPHX2 (0.33) | LMNAEPHX2 | |
| SCHEMBL7940982 | 0.82 | LMNA (0.46) | LMNAEPHX2 | |
| SCHEMBL29891804 | 0.82 | SMN1; SMN2 (0.42) | LMNAEPHX2 | |
| SCHEMBL9011650 | 0.82 | ALOX5 (0.33) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514812-B1 | Fragrance compositions and compounds | GIVAUDAN SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| EP-2514812-A2 | Fragrance compositions and compounds | Givaudan Nederland Services B.V. (NL) | 2012-10-24 | — | — | EP | disclosed |
| EP-2514812-A2 | Fragrance compositions and compounds | Givaudan Nederland Services B.V. (NL) | 2012-10-24 | — | — | EP | disclosed |
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| EP-2118249-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | Givaudan Nederland Services B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092678-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | LMNA 2425/4885RARB 918/4885PTPN1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.